AU2017268479B2 - Variant flavivirus envelope sequences and uses thereof - Google Patents

Variant flavivirus envelope sequences and uses thereof Download PDF

Info

Publication number
AU2017268479B2
AU2017268479B2 AU2017268479A AU2017268479A AU2017268479B2 AU 2017268479 B2 AU2017268479 B2 AU 2017268479B2 AU 2017268479 A AU2017268479 A AU 2017268479A AU 2017268479 A AU2017268479 A AU 2017268479A AU 2017268479 B2 AU2017268479 B2 AU 2017268479B2
Authority
AU
Australia
Prior art keywords
analogue
dengue
flavivirus
zika
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017268479A
Other languages
English (en)
Other versions
AU2017268479A1 (en
Inventor
Peter Laing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excivion Ltd
Original Assignee
Excivion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excivion Ltd filed Critical Excivion Ltd
Publication of AU2017268479A1 publication Critical patent/AU2017268479A1/en
Application granted granted Critical
Publication of AU2017268479B2 publication Critical patent/AU2017268479B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
AU2017268479A 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof Ceased AU2017268479B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
GB1608896.5 2016-05-20
PCT/US2017/033882 WO2017201543A1 (en) 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof

Publications (2)

Publication Number Publication Date
AU2017268479A1 AU2017268479A1 (en) 2018-12-06
AU2017268479B2 true AU2017268479B2 (en) 2021-04-01

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017268479A Ceased AU2017268479B2 (en) 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof

Country Status (18)

Country Link
US (2) US11028133B2 (enExample)
EP (2) EP3458471B1 (enExample)
JP (1) JP7121396B2 (enExample)
KR (1) KR20190008896A (enExample)
CN (1) CN109415414A (enExample)
AU (1) AU2017268479B2 (enExample)
BR (1) BR112018073681A2 (enExample)
CA (1) CA3025076A1 (enExample)
DK (1) DK3458471T3 (enExample)
GB (2) GB2550418A (enExample)
HU (1) HUE049543T2 (enExample)
IL (1) IL263054A (enExample)
MX (1) MX2018014198A (enExample)
PE (1) PE20190130A1 (enExample)
PH (1) PH12018502441A1 (enExample)
RU (1) RU2018142835A (enExample)
SG (1) SG11201810157QA (enExample)
WO (2) WO2017201543A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
US10849943B2 (en) * 2016-06-23 2020-12-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine compositions comprising an attenuated mutant Zika virus
EP3621645A4 (en) 2017-05-10 2021-01-27 University of Massachusetts BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
JP7725465B2 (ja) * 2019-11-07 2025-08-19 中国科学院微生物研究所 ジカ・デングワクチン及びその使用
CN117157524A (zh) * 2020-10-07 2023-12-01 赛诺菲巴斯德有限公司 改良的诊断测试
CA3198059A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
EP4602057A1 (en) * 2022-10-11 2025-08-20 University of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines

Also Published As

Publication number Publication date
DK3458471T3 (da) 2020-07-06
GB201719423D0 (en) 2018-01-03
AU2017268479A1 (en) 2018-12-06
BR112018073681A2 (pt) 2019-02-26
HUE049543T2 (hu) 2020-09-28
EP3458471A1 (en) 2019-03-27
US11401307B2 (en) 2022-08-02
GB2550418A (en) 2017-11-22
WO2018215495A1 (en) 2018-11-29
MX2018014198A (es) 2019-08-21
CA3025076A1 (en) 2017-11-23
RU2018142835A (ru) 2020-06-22
PE20190130A1 (es) 2019-01-17
US20200215180A1 (en) 2020-07-09
GB201608896D0 (en) 2016-07-06
IL263054A (en) 2019-01-31
US11028133B2 (en) 2021-06-08
CN109415414A (zh) 2019-03-01
KR20190008896A (ko) 2019-01-25
EP3630796A1 (en) 2020-04-08
US20190300580A1 (en) 2019-10-03
PH12018502441A1 (en) 2019-05-15
WO2017201543A1 (en) 2017-11-23
SG11201810157QA (en) 2018-12-28
JP2019520058A (ja) 2019-07-18
JP7121396B2 (ja) 2022-08-18
EP3458471B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
US11028133B2 (en) Modified flavivirus envelope sequences comprising unique glycosylation sites
TWI803521B (zh) 免疫原性屈公病毒
CN108040484B (zh) 基于慢病毒载体的日本脑炎免疫原性组合物
AU716676B2 (en) Subunit vaccine against flavivirus infection
CN112980852B (zh) 新型冠状病毒b.1.351南非突变株rbd的基因及其应用
CA2443781A1 (en) Core-glycosylated hcv envelope proteins
CN107074913A (zh) 包含非结构蛋白的片段的登革热病毒嵌合多表位及其在抗登革热病毒感染的免疫原性组合物中的用途
AU2006310173B2 (en) A lentiviral vector-based vaccine
WO2018200742A1 (en) Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US8222029B2 (en) Lentiviral vector-based vaccine
US20050069865A1 (en) Synthetic hcv envelope proteins and their use for vaccination
CN113025638B (zh) 一种基于双链核酸的折纸结构及其制备方法和应用
HK1261267A1 (en) Variant flavivirus envelope sequences and uses thereof
EA048051B1 (ru) Вакцины на основе мутантных calr и jak2 и способы их применения
AU2014231735A1 (en) Immunogenic compositions and a process for producing same
BR112017004770B1 (pt) Partícula tipo vírus compreende uma proteína envelope de flavivírus,seu método de produção, composição que a compreende e método de produzir um anticorpo
JP2004522697A (ja) Ｅｉａｖキメラワクチンおよび診断

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired